Zealand Pharma: FDA Issues CRL For Dasiglucagon In Congenital Hyperinsulinism
9/10 02:53
(RTTNews) - Zealand Pharma A/S (ZEAL) said that the U.S. Food and Drug Administration has issued a Complete Response Letter or CRL for Part 1 of the New Drug Application or NDA for dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age a...